vimarsana.com

Page 31 - டஃப்ட்ஸ் பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tufts Medical Center & Prapela Receive $2 5 Million award from NIH to Support Prapela s Development of Hospital Bassinet Pad for Opioid-Exposed Newborns

Share this article Share this article BIDDEFORD, Maine, June 9, 2021 /PRNewswire/ Tufts Medical Center and Prapela, an infant health company in Biddeford, ME, have been awarded a joint $2.5 million grant from the National Institute on Drug Abuse through the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, to help advance the development of the Prapela SVS Hospital Bassinet for the treatment of newborns diagnosed with Neonatal Abstinence Syndrome (NAS)/Neonatal Opioid Withdrawal Syndrome (NOWS). Tufts Medical Center & Prapela Receive $2.5 Million award from NIH to Support Prapela s Development of Hospital Bassinet Pad for Opioid-Exposed Newborns Tufts Medical Center & Prapela Receive $2.5 Million Award from NIH for NAS/NOWS Breakthrough Study

Pfizer Advances Its COVID-19 Vaccine Trial for Children 11 and Younger

Pfizer Advances Its COVID-19 Vaccine Trial for Children 11 and Younger With vaccines expected to be available to this age group as soon as this fall Pfizer says it’s moving forward with its Phase 2/3 trial in the pediatric population and expects to provide the COVID-19 vaccine to children between the ages of 5–11 in the fall, and soon after for those 4 and younger, if studies show immune response and safety. “If safety and immunogenicity is confirmed, and pending authorization or approval from regulators, we hope to submit the vaccine for potential Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) sometime in September-October timeframe for children 5–11, and soon after for 6 months to 5,” Pfizer stated.

For Black kidney patients, an algorithm may help perpetuate harmful racial disparities

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.